Liver Fibrosis Clinical Trials

31 recruitingLast updated: June 18, 2026

There are 31 actively recruiting liver fibrosis clinical trials across 42 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4. Top locations include Shanghai, China, San Antonio, Texas, United States, Hangzhou, China. Updated daily from ClinicalTrials.gov.


Liver Fibrosis Trials at a Glance

31 actively recruiting trials for liver fibrosis are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Not Applicable with 7 trials, with the heaviest enrollment activity in Shanghai, San Antonio, and Hangzhou. Lead sponsors running liver fibrosis studies include AstraZeneca, Beijing Continent Pharmaceutical Co, Ltd., and University Hospital, Angers.

Browse liver fibrosis trials by phase

Treatments under study

About Liver Fibrosis Clinical Trials

Looking for clinical trials for Liver Fibrosis? There are currently 30 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Liver Fibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Liver Fibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 31 trials

Recruiting
Not Applicable

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients

Liver FibrosisNon-alcoholic Fatty Liver Disease NAFLDAlcoholic Liver Disease (ALD)
University Hospital, Angers1,788 enrolled13 locationsNCT05699018
Recruiting
Phase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled526 locationsNCT06632444
Recruiting
Phase 2

Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

Hepatic CirrhosisLiver Fibrosis
AstraZeneca104 enrolled19 locationsNCT07610837
Recruiting

Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease

Liver FibrosisChronic Liver Disease (CLD)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine65 enrolled1 locationNCT07588854
Recruiting
Phase 1

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

Hepatic CirrhosisLiver Fibrosis
AstraZeneca12 enrolled2 locationsNCT07069725
Recruiting
Phase 2

A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis

Chronic Hepatitis B-related Liver Fibrosis
Beijing Continent Pharmaceutical Co, Ltd.150 enrolled1 locationNCT07417553
Recruiting

Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

Liver NeoplasmLiver FibrosisHBV Infection+1 more
Nanfang Hospital, Southern Medical University240 enrolled1 locationNCT07265544
Recruiting

Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis

Liver Fibrosis
Chinese University of Hong Kong200 enrolled1 locationNCT04429100
Recruiting

Incidence of Liver Disease-Related Outcomes in People With HIV

Liver FibrosisHIVHepatic Steatosis+3 more
Shanghai Public Health Clinical Center320 enrolled2 locationsNCT06940375
Recruiting

MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B

Liver FibrosisChronic Hepatitis B
Shengjing Hospital600 enrolled1 locationNCT06779058
Recruiting

City-Hospital Collaboration for Early Detection of Liver Fibrosis in Primary Care: A Secondary Prevention Project in the Grenoble Health Area

Liver Fibrosis
University Hospital, Grenoble150 enrolled2 locationsNCT07031089
Recruiting
Phase 2

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

Liver FibrosisNonalcoholic Steatohepatitis
VA Office of Research and Development128 enrolled1 locationNCT05526144
Recruiting
Not Applicable

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

Non alcoholic steato hepatitis (NASH)Liver Fibrosis/NASHMetabolic dysfunction–associated steatotic liver disease (MASLD)
Université de Sherbrooke36 enrolled1 locationNCT06843148
Recruiting

Non-invasive Assessment of Liver Fibrosis in a French Cohort of Pediatric Patients With Type III Glycogen Storage Disease: Current State and Perspectives

Liver Fibrosis
University Hospital, Strasbourg, France30 enrolled1 locationNCT07303140
Recruiting
Not Applicable

Research on the Protective Effects of Phycocyanin Against Liver Fibrosis and Cirrhosis

Liver CirrhosisLiver Fibrosis
Second Affiliated Hospital, School of Medicine, Zhejiang University10 enrolled1 locationNCT07271576
Recruiting
Not Applicable

SCREaning of Advanced Liver Fibrosis Using Non-Invasive Tests in General Population

ScreeningAdvanced Liver Fibrosis
University Hospital, Angers502 enrolled6 locationsNCT05880173
Recruiting
Not Applicable

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Insulin Sensitivity/ResistanceObesityInsulin Resistance+16 more
Pichamol Jirapinyo, MD, MPH132 enrolled2 locationsNCT06138821
Recruiting
Phase 1

Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

Cirrhosis, LiverLiver FibrosisAscites Hepatic
PharmaIN74 enrolled9 locationsNCT05490888
Recruiting
Phase 4

Fibrosis Lessens After Metabolic Surgery

Metabolic dysfunction-associated steatohepatitis (MASH)ObesityNon-Alcoholic Fatty Liver Disease+2 more
Ali Aminian120 enrolled22 locationsNCT06374875
Recruiting

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Cirrhosis, LiverLiver FibrosisLiver Steatoses+5 more
Foundation for the National Institutes of Health400 enrolled4 locationsNCT07122700